Hydroquinone for skin lightening: Safety profile, duration of use and when should we stop?

Journal of Dermatological Treatment

Volumn 21, Issue 5, 2010, Pages 272-275

  Tse, Tsz Wah ^a  

^a 14/F Manning House ^*  (Hong Kong)

Author keywords

Exogenous ochronosis; Hydroquinone; Hyperpigmentation

Indexed keywords

HYDROQUINONE;

DRUG SAFETY; HUMAN; NEPHROTOXICITY; OCHRONOSIS; PRIORITY JOURNAL; REVIEW; SKIN COLOR; SKIN LIGHTENING;

CONSUMER PRODUCT SAFETY; DERMATOLOGIC AGENTS; HUMANS; HYDROQUINONES; MELANOCYTES; PIGMENTATION DISORDERS; SKIN PIGMENTATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 77955439188     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903341945     Document Type: Review

References (31)

1. Burke PA, Maibach HI. Exogenous ochronosis: An overview. J Dermatol Treat. 1997;8:21-26.
2. Hydroquinone Task Group, Nonprescription Drug Manufacturers Association. Salient observations from the publishedliterature on exogenous ochronosis reportedly associated with skin discoloration fade products. Washington, DC: Nonprescription Drug Manufacturers Association; 12 May
3. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20:308-313.
4. Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20:781-787.
5. Levitt J. The safety of hydroquinone: A dermatologist's response to the 2006 Federal Register. J Am Acad Dermatol. 2007;57:854-872.
6. Toombs EL. Hydroquinone - What is its future? Dermatol Ther. 2007;20:149-156.
7. Westerho W, Kooyers TJ. Hydroquinone and its analogues in dermatology - A potential risk. J Cosmet Dermatol. 2005;4:55-59.
8. Nordlund J, Grimes P, Ortonne J-P. Letters to the editor: The safety of hydroquinone. J Cosmet Dermatol. 2006; 5:168-170.
9. Palm MD, Toombs EL. Hydroquinone and the FDA - The debate? J Drugs Dermatol. 2007;6:122.
10. O'Donoghue JL. Twenty-fourth Commission Directive 2000/ 6/EC. Official J Eur Commun. 2000;L56:42-46
11. Halder RM, Richards GM. Management of dischromias in ethnic skin. Dermatologic Therapy. 2004;17:151-157.
12. Goldsmith LA. Cutaneous changes in errors of amino acid metabolism: Alkaptonuria. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in general medicine. Chap 148. New York: McGraw Hill; p. 1841-1845
13. Offel JV, DeClerck L, Francx L, Stevens WJ. The clinical manifestations of ochronosis: A review. Acta Clin Belg. 1995;50:358-362.
14. Dogliotti M, Leibowitz M. Granulomatous ochronosis: A cosmetic-induced skin disorder in blacks. S Afr Med J. 1979;56:757-760.
15. Cheryl YL, Maibach H. Exogenous ochronosis: An update on clinical features, causative agents and treatment options. Am J Clin Dermatol. 2001;2:213-217.
16. Findlay GH, LMorrison JG, Simson IW. Exogenous ochro- nosis and pigmented colloid millium from hydroquinone bleaching creams. J Dermatol. 1975;93:613-622.
17. Siak KT, Chee SS, Chee LG. Hydroquinone-induced exogenous ochronosis in Chinese - Two case reports and a review. Int J Dermatol. 2008;47:639-640.
18. Charlin R, Barcaui CB, Kac BK, Soares DB, Rabello- Fonseca R, Azulay-Abulafia L. Hydroquinone-induced exogenous ochronosis: A report of four cases and usefulness of dermoscopy. Int J Dermatol. 2008;47:19-23.
19. Diven DG, Smith EB, Pupo RA, Mike Lee. Hydroquinone- induced localized exogenous ochronosis treated with dermabra- sion and CO2 laser. J Dermatol Surg Oncol. 1990;16:1018-1022.
20. Olumide YM, Akinkugbe AO, Altraide D, Mohammed T, Ahamefule N, Ayanlono S, et al. Complications ofchronic use of skin lightening cosmetics. Int J Dermatol. 2008;47:344-353
21. Ruocco V, Florio M. Fish-odor syndrome: An olfactory diagnosis. Int J Dermatol. 1995;34:92-93.
22. Touart D, Sau P. Cutaneous deposition diseases. Part II. J Am Acad Dermatol. 1998;39:527-544.
23. Hoshaw RA, Zimmerman KG, Menter A. Ochronosis-like pigmentation from hydroquinone bleaching creams in American blacks. Arch Dermatol. 1985;121:105-108.
24. DeCaprio AP. The toxicology of hydroquinone - Relevance to occupational and environmental exposure. Crit Rev Toxicol. 1999;29:283-330.
25. O'Donoghue JL. Hydroquinone and its analogues in dermatology - A risk-benefit viewpoint. J Cosmet Dermatol. 2006;5:196-203.
26. National Toxicology Program. Toxicology and carcinogenesis studies of hydroquinone in F-344/N rats and B6C3F1 mice. Research Triangle Park, NC: National Institutes of Health; 1989. Publication No. 90-2821.
27. International Agency for Research on Cancer. Hydroquinone. In: IARC monographs on the evaluation of carcinogenic risks to humans: Re-evaluation of some organic chemicals. Hydra- zine and hydrogen peroxide. Vol.71, Part 2. Geneva: World Health Organization; 1999. p. 691-719.
28. Pifer JW, Herane FT, Swanson FA, John L. O'Donoghue. Mortality study of employees engaged in the manufacture and use of hydroquinone. Int Arch Occup Environ Health. 1995;67:267-280.
29. Bellew SG, Alster TS. Treatment of exogenous ochronosis with a Q-switched alexandrite (755 nm) laser. Dermatol Surg. 2004;30:555-558.
30. Lacz NL, Vafaie J, Kihiczak NI. Postinflammatory hyperpigmentation: A common but troubling condition. Int J Dermatol. 2004;43:362-365.
31. Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91-98.